Internal link ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 Abril 15, 2019 at 11:00 AM UTC
Internal link ProQR to Present at the H.C. Wainwright Global Life Sciences Conference Abril 01, 2019 at 11:00 AM UTC
Internal link ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership Março 26, 2019 at 08:01 PM UTC
Internal link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2 Março 11, 2019 at 04:45 PM UTC
Internal link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 Março 11, 2019 at 12:00 PM UTC
Internal link ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results Fevereiro 27, 2019 at 12:00 PM UTC
Internal link ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day Janeiro 29, 2019 at 01:30 PM UTC
Internal link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10 Janeiro 07, 2019 at 12:00 PM UTC
Internal link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2 Janeiro 02, 2019 at 12:00 PM UTC